Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 289

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 289
---
 amount of approximately $3.86 million. The National Institute on Aging (NIA) awarded DiamiR approximately $3.36 million in a Commercialization Readiness Pilot (CRP) grant as part of its Small Business Innovation Research (SBIR) program. The award builds upon earlier studies conducted by DiamiR in collaboration with leading academic centers and continues to support development of CogniMIR ®, DiamiR’s lead diagnostic product candidate for early detection and monitoring of mild cognitive impairment and AD. The second award of $498,572 was granted to DiamiR by the National Institute for Neurological Disorders and Stroke (NINDS) for a project entitled “Circulating Organ-enriched microRNAs as biomarkers of Rett Syndrome.” DiamiR has received non-dilutive funding to support its work. Below is a summary of DiamiR’s awards to date:

| * | indicates grants from the National Institutes of Health (NIH). |

NIH/NIA SBIR CRP Grant Number 2R44AG044860-07 09/01/2020 – 04/30/2024 Title: Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer’s disease Analytical validation of CogniMIR ®miRNA panel, and other studies supporting commercialization of the test within a CLIA/CAP laboratory. NIH/NINDS SBIR Phase I Grant Number R43NS115212. 09/30/2020 – 03/30/2023 Title: Circulating organ-enriched microRNAs as biomarkers of Rett syndrome. NIH/NIA SBIR Phase IIB Grant Number 2R44AG044860-04 03/01/2017 – 08/28/2020 Title: Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer’s disease. The main goal of this Phase IIB study is to establish reliable pre-analytical protocol and analytical workflow for detection of brain-enriched microRNAs in plasma of AD patients and control subjects. NIH/NIA, Grant Number 3R44AG044860-06S1 (Admin. Suppl.) 09/01/2019 – 02/28/2020 Title: Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer’s disease. Alzheimer’s Drug Discovery Foundation. Ref #: 201809-2016425 11/11/2019 –